2014
DOI: 10.1007/s12185-013-1497-3
|View full text |Cite
|
Sign up to set email alerts
|

Peptide vaccines for hematological malignancies: a missed promise?

Abstract: Despite the crucial aid that newly developed target therapies are providing to chemotherapy and stem cell transplant, the cure for many hematological malignancies is still an unmet need. Although available therapies are able to induce an effective debulking of the tumor, most of the time, an insidious minimal residual disease survives current treatments and it is responsible for an immediate or delayed relapse. Peptide-derived antitumor vaccines have been developed with the idea that an artificially ''educated… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 75 publications
0
6
0
Order By: Relevance
“…Tumor antigens are classified according to their distribution as tumor-specific antigens (TSA), which are only expressed by the tumor, or as tumor-associated antigens (TAA), which can also be found in other normal cell types [11,1316]. Unique tumor antigens, on the other hand, are those of patient-restricted expression whereas shared antigens are commonly present across various samples of the same histologic subtype of malignancy and on different tumor types, but not in normal tissues, except for testis and placenta.…”
Section: Classification Of Tumor Antigensmentioning
confidence: 99%
“…Tumor antigens are classified according to their distribution as tumor-specific antigens (TSA), which are only expressed by the tumor, or as tumor-associated antigens (TAA), which can also be found in other normal cell types [11,1316]. Unique tumor antigens, on the other hand, are those of patient-restricted expression whereas shared antigens are commonly present across various samples of the same histologic subtype of malignancy and on different tumor types, but not in normal tissues, except for testis and placenta.…”
Section: Classification Of Tumor Antigensmentioning
confidence: 99%
“…Thus, different approaches will be necessary for further improvements in clinical outcomes. Immunotherapies include cell-mediated immunotherapy, vaccination, cytokine therapy, antibody therapy, and biological response modifiers therapy, but their effects are currently limited [20,21]. Immunological tolerance is one of the mechanisms by which cancer cells escape host defense surveillance.…”
Section: Discussionmentioning
confidence: 99%
“…GEL is a polymer adjuvant based on the dispersion of highly stable sodium polyacrylate gel particles in water; IMS is a combination of micro-emulsions and an immunostimulating compound containing a special fortified mineral oil; ISA is an adjuvant consisting of a mineral oil and a surfactant from the mannide monooleate family, which can be used in the form of various types of emulsions: water-in-oil (W/O), oil-in-water (O/W) or water-in-oil-in-water (W/O/W)), cytokines such as GM-CSF, or peptides loaded into the APC [122][123][124]. A lot of different peptide-based vaccines are used for the treatment of numerous types of cancers such as glioma [125], breast cancer [126], hematopoietic tumors [127], renal cell carcinoma [128] and others. However, the peptide-based vaccination is weakly immunogenic for killing large tumors.…”
Section: Peptide-based Therapeutic Vaccinesmentioning
confidence: 99%